Protara Therapeutics, Inc.
US ˙ NasdaqGM ˙ US74365U1079

SecurityTARA / Protara Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership556,974 shares
Latest Disclosed Value $ 2,901,834
Morgan Stanley reports 217.67% increase in ownership of TARA / Protara Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 556,974 shares of Protara Therapeutics, Inc. (US:TARA) valued at $2,901,835 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 175,329 shares of Protara Therapeutics, Inc.. This represents a change in shares of 217.67% during the quarter. The current value of the position is $2,317,012 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F PROTARA THERAPEUTICS COM STK 74365U107 556,974 381,645 217.67 2,902 210.60 0.0002
2026-05-27 2025-12-31 13F/A-1 PROTARA THERAPEUTICS COM STK 74365U107 175,329 66,785 61.53 935 97.88 0.0001
2026-02-13 2025-12-31 13F PROTARA THERAPEUTICS COM STK 74365U107 175,329 66,785 935
2026-05-27 2025-09-30 13F/A-1 PROTARA THERAPEUTICS COM STK 74365U107 108,544 -20,371 -15.80 472 21.03 0.0000
2025-11-14 2025-09-30 13F PROTARA THERAPEUTICS COM STK 74365U107 108,544 -20,371 472 0.0000
2025-08-15 2025-06-30 13F PROTARA THERAPEUTICS COM STK 74365U107 128,915 62,700 94.69 391 38.30 0.0000
2025-05-15 2025-03-31 13F PROTARA THERAPEUTICS COM STK 74365U107 66,215 -33,312 -33.47 282 -46.29 0.0000
2025-05-15 2024-12-31 13F/A-1 PROTARA THERAPEUTICS COM STK 74365U107 99,527 99,527 526 0.0000
2025-02-14 2024-12-31 13F PROTARA THERAPEUTICS COM STK 74365U107 99,527 99,527 526 0.0000
2023-08-14 2023-06-30 13F PROTARA THERAPEUTICS COM STK 74365U107 0 -58,364 -100.00 0 -100.00
2023-05-15 2023-03-31 13F PROTARA THERAPEUTICS COM STK 74365U107 58,364 58,339 233,356.00 183 0.0000
2023-02-14 2022-12-31 13F PROTARA THERAPEUTICS COM STK 74365U107 25 -219 -89.75 0 -100.00 0.0000
2022-11-14 2022-09-30 13F PROTARA THERAPEUTICS COM STK 74365U107 244 -2,210 -90.06 1 -85.71 0.0000
2022-10-27 2022-06-30 13F/A-1 PROTARA THERAPEUTICS COM STK 74365U107 2,454 -4,102 -62.57 7 -78.79 0.0000
2022-08-15 2022-06-30 13F PROTARA THERAPEUTICS COM STK 74365U107 2,454 -4,102 7 0.0000
2022-10-27 2022-03-31 13F/A-1 PROTARA THERAPEUTICS COM STK 74365U107 6,556 -21,344 -76.50 33 -82.45 0.0000
2022-05-13 2022-03-31 13F PROTARA THERAPEUTICS COM STK 74365U107 6,556 -21,344 33 0.0000
2022-02-14 2021-12-31 13F PROTARA THERAPEUTICS COM STK 74365U107 27,900 1,318 4.96 188 2.17 0.0000
2021-11-15 2021-09-30 13F PROTARA THERAPEUTICS COM STK 74365U107 26,582 -22,302 -45.62 184 -61.26 0.0000
2021-08-23 2021-06-30 13F/A-1 PROTARA THERAPEUTICS COM STK 74365U107 48,884 47,528 3,505.01 475 2,161.90 0.0001
2021-08-16 2021-06-30 13F PROTARA THERAPEUTICS COM STK 74365U107 48,884 47,528 475 0.0000
2021-05-17 2021-03-31 13F PROTARA THERAPEUTICS COM STK 74365U107 1,356 -4,148 -75.36 21 -84.33 0.0000
2021-02-16 2020-12-31 13F PROTARA THERAPEUTICS COM STK 74365U107 5,504 5,270 2,252.14 134 3,250.00 0.0000
2020-11-13 2020-09-30 13F PROTARA THERAPEUTICS COM STK 74365U107 234 -419 -64.17 4 -78.95 0.0000
2020-08-14 2020-06-30 13F PROTARA THERAPEUTICS COM STK 74365U107 653 653 19 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.